Search Results 8821-8830 of 42376 for oral

1. Mouth cancer - Doctors and departments - Mayo Clinic

   Learn what healthcare professionals look for when diagnosing mouth cancer. Find out about oral cancer treatments, including surgery, chemotherapy and ...

2. Science Saturday: A new era in migraine care - Mayo Clinic News Network

   “This has been a life-changing experience for some of my patients, who have been able to stop taking some of their oral medications,” Dr. Starling says ...

3. Mayo Clinic Health Letter: Highlights from the March 2014 Issue

   Celiac disease or lactose intolerance can be treated with dietary changes. If underlying problems are not correctable, oral vitamin and mineral supplements may ...

4. Orthopedic Surgery - Clinical trials

   Jacksonville, Fla. The purpose of this study is to evaluate the orthopedic patients' perspective on the use of indwelling foley catheters. Postoperative Oral ...

5. A Study Of The Effect Of IW-1973 On The Exercise Capacity Of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) - Mayo Clinic

   The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or without permanent or persistent atrial fibrillation ...

6. Dermatology - Doctors - Mayo Clinic

   edema, Stevens-Johnson syndrome, Dermatitis, Oral lichen planus, Contact dermatitis, Erythromelalgia. Show more areas of focus for Mark Denis P. Davis, M.D. ...

7. Dermatology - Doctors - Mayo Clinic

   ning mouth syndrome, Oral lichen planus, Skin cancer, Skin problems, Dermatitis, Hair loss, Morphea, Canker sores, Hemangioma, Vascular birthmarks, Melanoma ...

8. A Study to Evaluate ALZT-OP1a in Subjects with Mild-to-Moderate Amyotrophic Lateral Sclerosis - Mayo Clinic

   Inability to tolerate the administration of an oral inhaled powder via dry powder inhaler (DPI). Has taken any investigational study drug within 30 days or ...

9. Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors - Mayo Clinic

   - Ability to swallow and retain oral medications. Exclusion Criteria: - Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor ...

10. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation - Mayo Clinic

    oral agent. - Unable or unwilling to swallow study drug. - Uncontrolled intercurrent illness. - Known hypersensitivity to fluoropyrimidine or leucovorin ...